



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

**Group Art Unit:** 

Kenji DOSAKA et al

Examiner:

Application No.: New Application

Attorney Dkt. No.: 107348-00102

Filed: May 11, 2001

- -----

PLASMA REACTOR AND METHOD OF DETERMINING

ABNORMALITY IN PLASMA REACTOR

disclosed information.

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents Washington, D.C. 20231

May 11, 2001

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

 $\boxtimes$ This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date or the date of filing a CPA, OR (b) before the mailing date of a first Office Action on the merits in the present application, or (c) accompanies a Request for Continued Examination. No certification or fee is required.  $\Box$ This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1). I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).  $\Box$ A check in the amount of \$240.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment

to Deposit Account No. 01-2300 as needed to ensure consideration of the

- П This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$130.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.  $\Box$ I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1). П I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making
- 4. The relevance of the non-English language reference(s) is discussed in the present specification.

Disclosure Statement. 37 CFR §1.97(e)(2).

reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information

Respectfully submitted,

Charles M. Marmelstein Registration No. 25,895

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 Connecticut Avenue, N.W., Suite 600 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

CMM:mmg

Enclosures: PTO-1449 Form; Reference (1)